We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 8,539

Comparison of the proposed rule to the final rule - Medicare program; reporting and returning of overpayments
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 12 2016

For the reasons set forth in the preamble, the Centers for Medicare & Medicaid Services proposes to amend Chapter amends 42 CFR chapter IV as set


Judicial Redress Act passes the House with the Senate Amendments
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • European Union, USA
  • February 11 2016

The amended Judicial Redress Act has passed the House and is on its way to the president to be signed into law. The Act, which we covered in an


The Final 60-Day Rule Is Finally Here!
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 11 2016

The Centers for Medicare & Medicaid Services (CMS) has finally published the long-awaited final rule establishing a process for Medicare Part A and B


Zika Virus: Appropriate Workplace Responses
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 11 2016

The Zika virus has been the topic of much discussion and anxiety for many weeks. The United States Centers for Disease Control and Prevention (CDC


Now Trending on Twitter: Will you be my HealthPolicyValentines?
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 11 2016

In 2012, an HHS staffer named Emma Sandoe created the Twitter hashtag, HealthPolicyValentines. It was a way for health policy geeks on Twitter to


First Monoclonal Antibody Biosimilar in U.S. Gets One Step Closer to FDA Approval
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 10 2016

Yesterday, the FDA's Arthritis Advisory Committee voted 21-3 to recommend that CT-P13, Celltrion's proposed biosimilar of Janssen Biotech, Inc.'s


CMS Takes Action Against Network Transparency While New Jersey Legislation Hits a Snag
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 10 2016

Just as the Centers for Medicare & Medicaid Services (CMS) began holding federal health care plans accountable for their provider network


Amended version of Judicial Redress Act passes the Senate; now goes back to the House
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • European Union, USA
  • February 10 2016

The US Senate passed the amended version of the Judicial Redress Act on February 9. The amendments, which tie the Umbrella Agreement to Safe Harbor 2


Deciphering the Final AMP Rule - Key Provisions Impacting Pharmacies, PBMs, and Manufacturers
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 10 2016

In late January, the Centers for Medicare & Medicaid Services ("CMS") released the much anticipated Covered Outpatient Drugs Final Rule with Comment


2016 ALTANSPS (formerly ALTAACSM) Land Title Survey Standards
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 10 2016

On February 23, 2016, the 2016 Minimum Standard Detail Requirements for ALTANSPS Land Title Surveys will become effective (superseding the 2011